Yüklüyor......
Drug repurposing in autosomal dominant polycystic kidney disease: back to the future with pioglitazone
Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited cause of end-stage kidney failure. At present, only one drug, tolvaptan, has been approved for use to slow disease progression, but its use is limited by reduced tolerability and idiosyncratic liver toxicity. Thiazolid...
Kaydedildi:
| Yayımlandı: | Clin Kidney J |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Oxford University Press
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8243263/ https://ncbi.nlm.nih.gov/pubmed/34221378 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfab062 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|